Feng Hui, the legal representative and executive director of Shanghai Junshi Biomedical Technology Co., Ltd., has been engaged in the research and development of new drugs for nearly 20 years, mainly involving the formulation of global development strategy of new drugs, molecular design, humanization, affinity maturation, establishment of high-yield cell lines, process development and production technology transfer of antibodies and macromolecular protein drugs. Participated in the development of nearly 20 monoclonal antibody products with high technical threshold and independent intellectual property rights, and has a number of invention patents. Therefore, it can be considered that Feng Hui is engaged in the research and development of new drugs in the biomedical industry.